Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges

  • Trends Cancer. 2017 Jun;3(6):391-406. doi: 10.1016/j.trecan.2017.04.008.
Aneta Gandalovičová  1 ,  Daniel Rosel  1 ,  Michael Fernandes  2 ,  Pavel Veselý  3 ,  Petr Heneberg  4 ,  Vladimír Čermák  1 ,  Luboš Petruželka  5 ,  Sunil Kumar  6 ,  Victoria Sanz-Moreno  7 ,  Jan Brábek  8
Affiliations
  • 1. Department of Cell Biology, Charles University, Viničná 7, Prague, Czech Republic; Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (BIOCEV), Průmyslová 595, 25242, Vestec u Prahy, Czech Republic.
  • 2. Medbase, Chapel Hill, NC, USA.
  • 3. Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic.
  • 4. Charles University, Department of Internal Medicine, Third Faculty of Medicine, Prague, Czech Republic.
  • 5. Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • 6. Ayurveda Molecular Modeling, Hyderabad, Telangana, India.
  • 7. Tumor Plasticity Laboratory, Randall Division of Cell and Molecular Biophysics, Guy's Campus, King's College London, London, UK. Electronic address: [email protected].
  • 8. Department of Cell Biology, Charles University, Viničná 7, Prague, Czech Republic; Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (BIOCEV), Průmyslová 595, 25242, Vestec u Prahy, Czech Republic. Electronic address: [email protected].
PMID: 28670628 DOI: 10.1016/j.trecan.2017.04.008
Abstract

In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of Anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term 'migrastatics' for drugs interfering with all modes of Cancer cell invasion and metastasis, to distinguish this class from conventional cytostatic drugs, which are mainly directed against cell proliferation. We define actin polymerization and contractility as target mechanisms for migrastatics, and review candidate migrastatic drugs. Critical assessment of these antimetastatic agents is warranted, because they may define new options for the treatment of solid cancers.

Keywords
contractility; invasion; metastasis; migrastatics; solid cancer; treatment.
Products